Charles Schwab Investment Management Inc Madrigal Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

$527 Billion
Q4 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 150,746 shares of MDGL stock, worth $49.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

150,746

Previous 147,970 1.88%

Holding current value

$49.4 Million

Previous $31.4 Million 48.13%

% of portfolio

0.01%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$202.45 - $354.85 $562,001 - $985,063	2,776 Added 1.88%	150,746 $46.5 Million
Q3 2024 Nov 12, 2024	BUY	$212.22 - $292.96 $2.05 Million - $2.83 Million	9,656 Added 6.98%	147,970 $31.4 Million
Q2 2024 Aug 12, 2024	BUY	$193.33 - $291.99 $3.02 Million - $4.56 Million	15,622 Added 12.73%	138,314 $38.8 Million
Q1 2024 May 08, 2024	BUY	$171.37 - $283.23 $424,997 - $702,410	2,480 Added 2.06%	122,692 $32.8 Million
Q4 2023 Feb 06, 2024	BUY	$120.4 - $237.13 $1.29 Million - $2.54 Million	10,711 Added 9.78%	120,212 $27.8 Million
Q3 2023 Nov 08, 2023	BUY	$146.04 - $225.78 $1.62 Million - $2.5 Million	11,083 Added 11.26%	109,501 $16 Million
Q2 2023 Aug 09, 2023	BUY	$203.88 - $312.0 $1.39 Million - $2.12 Million	6,796 Added 7.42%	98,418 $22.7 Million
Q1 2023 May 11, 2023	BUY	$231.06 - $307.08 $39,742 - $52,817	172 Added 0.19%	91,622 $22.2 Million
Q4 2022 Feb 13, 2023	BUY	$58.39 - $296.54 $115,086 - $584,480	1,971 Added 2.2%	91,450 $26.5 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $74,440 - $97,717	1,229 Added 1.39%	89,479 $5.82 Million
Q2 2022 Aug 15, 2022	SELL	$58.04 - $100.2 $13,000 - $22,444	-224 Reduced 0.25%	88,250 $6.32 Million
Q1 2022 May 13, 2022	BUY	$55.89 - $101.89 $98,142 - $178,918	1,756 Added 2.02%	88,474 $8.68 Million
Q4 2021 Feb 11, 2022	BUY	$72.34 - $95.09 $278,509 - $366,096	3,850 Added 4.65%	86,718 $7.35 Million
Q3 2021 Nov 16, 2021	BUY	$78.35 - $105.02 $829,413 - $1.11 Million	10,586 Added 14.65%	82,868 $6.61 Million
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $770,115 - $1.09 Million	7,923 Added 12.31%	72,282 $7.04 Million
Q1 2021 May 17, 2021	BUY	$108.54 - $125.2 $452,720 - $522,209	4,171 Added 6.93%	64,359 $7.53 Million
Q4 2020 Feb 16, 2021	BUY	$110.06 - $133.7 $96,082 - $116,720	873 Added 1.47%	60,188 $6.69 Million
Q3 2020 Nov 13, 2020	SELL	$99.78 - $124.21 $230,192 - $286,552	-2,307 Reduced 3.74%	59,315 $7.04 Million
Q2 2020 Aug 14, 2020	BUY	$60.13 - $125.71 $203,359 - $425,151	3,382 Added 5.81%	61,622 $6.98 Million
Q1 2020 May 15, 2020	BUY	$66.76 - $93.49 $229,053 - $320,764	3,431 Added 6.26%	58,240 $3.89 Million
Q4 2019 Feb 07, 2020	BUY	$84.28 - $118.5 $545,881 - $767,524	6,477 Added 13.4%	54,809 $4.99 Million
Q3 2019 Nov 08, 2019	BUY	$84.4 - $106.53 $85,666 - $108,127	1,015 Added 2.15%	48,332 $4.17 Million
Q2 2019 Aug 09, 2019	BUY	$91.13 - $142.5 $221,172 - $345,847	2,427 Added 5.41%	47,317 $4.96 Million
Q1 2019 May 14, 2019	BUY	$103.48 - $143.84 $264,184 - $367,223	2,553 Added 6.03%	44,890 $5.62 Million
Q4 2018 Feb 14, 2019	SELL	$94.77 - $215.54 $56,956 - $129,539	-601 Reduced 1.4%	42,337 $4.77 Million
Q3 2018 Nov 13, 2018	BUY	$207.3 - $300.31 $6.14 Million - $8.89 Million	29,618 Added 222.36%	42,938 $9.2 Million
Q2 2018 Aug 08, 2018	BUY	$101.55 - $313.9 $344,457 - $1.06 Million	3,392 Added 34.17%	13,320 $3.73 Million
Q1 2018 May 07, 2018	BUY	$93.35 - $149.04 $102,685 - $163,944	1,100 Added 12.46%	9,928 $1.16 Million
Q4 2017 Jan 17, 2018	SELL	$39.35 - $97.37 $195,648 - $484,123	-4,972 Reduced 36.03%	8,828 $811,000
Q3 2017 Nov 13, 2017	BUY	$15.48 - $46.19 $213,624 - $637,422	13,800	13,800 $621,000

Others Institutions Holding MDGL

# of Institutions

337

Shares Held

22.3M

Call Options Held

960K

Put Options Held

940K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.61B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Madrigal Pharmaceuticals, Inc. Transaction History